The autoimmune thyroid diseases (AITDs), comprising Graves' disease (GD) and Hashimoto's thyroiditis (HT), appear to develop as a result of a complex interaction between predisposing genes and environmental triggers. The goals of the present study were to identify the susceptibility loci for GD and HT and to study the relationships between them. We performed a whole genome linkage study on a dataset of 56 multiplex, multigenerational AITD families (354 individuals), using 387 microsatellite markers. We identified 6 loci that showed evidence for linkage to AITD. Only one locus, on chromosome 6 [AITD-1; 80 centimorgans (cM)], was linked with both GD and HT [maximum LOD score (MLS), 2.9]. This locus was close to, but distinct from, the human leukocyte antigen region. One locus on chromosome 13 (HT-1; 96 cM) was linked to HT (MLS, 2
chromosome 12 (HT-2; 97 cM) was linked to HT in a subgroup of the families (MLS, 3.8). Three loci showed evidence for linkage with GD: GD-1 on chromosome 14 (99 cM; MLS, 2.5), GD-2 on chromosome 20 (56 cM; MLS, 3.5), and GD-3 on chromosome X (114 cM; MLS, 2.5). Since GD-2 showed the strongest evidence for linkage to GD we fine-mapped this locus to a 1-cM interval between markers at 55 and 56 cM on chromosome 20. These results demonstrated that 1) Graves' and Hashimoto's diseases are genetically heterogeneous, with only one locus in common to both diseases on chromosome 6; 2) only one HT locus was identified in all families, probably due to heterogeneity of the HT phenotype; and 3) three loci were shown to induce genetic susceptibility to GD by interacting with each other. One of them (GD-2) was fine-mapped to a 1-cM interval. (J Clin Endocrinol Metab 84: 4656 -4664, 1999) 
T HE AUTOIMMUNE thyroid diseases (AITDs) including
Graves' disease (GD) and Hashimoto's thyroiditis (HT), are the commonest human autoimmune diseases and are responsible for significant morbidity in premenopausal women. The AITDS are caused by immune responses to the thyroid gland. In Graves' disease the autoimmune process results in the production of thyroid-stimulating antibodies and leads to hyperthyroidism, whereas in Hashimoto's thyroiditis the end result is thyroid cell death and hypothyroidism (reviewed in Refs. 1 and 2). The pathogenesis of the AITDs involves a complex interaction between susceptibility genes (for a review, see Ref. 3 ) and environmental modulating factors (4) . Epidemiological evidence for a genetic predisposition to the AITDs is abundant: 1) the AITDs cluster in families (5) gives a sibling risk ratio ( s ) of more than 15 (6); 2) a high concordance rate has been reported for monozygotic twins compared to dizygotic twins (7, 8) ; and 3) thyroid autoantibodies, which may be markers of subclinical AITD, have been reported in up to 50% of siblings of patients with AITD (9, 10) .
Although the clinical presentations of GD and HT are different, they share many features in common: 1) humoral and cellular immune reaction to thyroid antigens (11) , 2) infiltration of the thyroid by T cells which are biased in their V gene use (12) , 3) female preponderance of the diseases (13) , and 4) strong familial predisposition (reviewed in Ref. 3) . Moreover, 1) GD and HT cluster in families (14) ; 2) there are reports of identical twins and triplets with GD and HT (15) ; and 3) in the same individual, GD can evolve into HT and vice versa (16) . Thus, it is possible that the genetic susceptibility to GD and HT is conferred by similar or related genes. However, the genes causing the AITDs have not been identified. Several candidate genes have been examined in the past for a possible contribution to genetic susceptibility to AITD, including human leukocyte antigen (HLA), but none of them proved to be a major susceptibility gene for AITD (for a review, see Ref. 3) .
By using the candidate gene approach, we and others have to date failed to identify major susceptibility loci for familial AITD. Therefore, we decided to screen the whole human genome. In a preliminary screen of candidate chromosomes, three loci were found to be linked with Graves' disease (17) (18) (19) . We have now extended these studies and completed a whole genome screen of a larger group of families with GD and HT. The aims of the present study were: 1) to identify the susceptibility loci for familial GD and HT using microsatellite-based whole genome screening; 2) to analyze the inter-actions between these loci, and 3) to study the genetic relationship between GD and HT. Our results suggested that the major genetic susceptibility to familial GD was conferred by three interacting loci with additive effects, and that the susceptibility to familial HT was mostly conferred by distinctive loci that did not interact with the GD loci. Only one locus showed evidence of linkage to both GD and HT, suggesting that this locus may harbor a gene conferring susceptibility to both diseases.
Subjects and Methods

Ascertainment of the study families
The project was approved by the institutional review board. Fifty-six families (354 individuals) were analyzed in the current study (28 from the U.S., 9 from Italy, 10 from Israel, and 9 from the UK). All families enrolled in the study were multiplex for AITD (Ͼ1 affected) and multigenerational. To study the genetic relationship between GD and HT, we included 20 families (36%) that were mixed with GD and HT first degree relatives.
Family ascertainment
Families were ascertained only through a patient with AITD, who confirmed having at least one other first degree relative with AITD. Although as many relatives as possible were recruited from each family, the minimum requirement for participation in the study was a family consisting of 4 first degree relatives (including the proband) from 2 generations. On the average, our families had 6.2 members.
Clinical assessment
The AITDs include GD and HT. GD was diagnosed by 1) documented clinical and biochemical hyperthyroidism requiring treatment, 2) diffuse goiter, 3) presence of TSH receptor antibodies, and/or 4) diffusely increased 131 I uptake in the thyroid gland. HT was diagnosed by 1) documented clinical and biochemical hypothyroidism requiring thyroid hormone replacement, and 2) presence of autoantibodies to thyroid peroxidase, with or without antibodies to thyroglobulin. Antithyroglobulin and anti-thyroid peroxidase antibodies were measured by specific RIA (Kronus, San Clemente, CA). All other family members, whether thyroid autoantibody positive or negative, were defined for this study as unaffected. For all subjects, phenotype was determined with the clinician blinded to the individual's genotype. Each participant was interviewed and examined, and gave written informed consent before participating. All pertinent clinical and laboratory data were recorded and stored in our database. At the time of the interview blood was collected for DNA purification as well as for thyroid function tests and thyroid antibody testing.
PCR amplification of microsatellite markers
DNA was extracted from whole blood as previously described (20) . For the whole genome screening we used the Perkin-Elmer Corp. microsatellite panels (version 1.0, panels 1-4, 20, and 25-28; version 2.0, panels 5-19 and 21-24; a total of 387 markers). In addition, oligonucleotides for amplification of the microsatellites used for fine mapping were designed according to published sequences in the genome database (http://gdbwww.gdb.org/). Microsatellite markers were selected from the Genethon linkage maps (21) and were analyzed according to the method of Weber (22) . Fluorescent-labeled primers were purchased from PE Applied Biosystems (Foster City, CA). PCR were performed in 15-L reaction volumes containing 50 ng of genomic DNA, 5 pmol of each primer (one of which was fluorescent labeled), PCR buffer containing 50 mmol/L KCl; 10 mmol/L Tris-HCl (pH 8. The PCR products were diluted 1:20 in ddH 2 O and pooled. Two microliters of the pooled products were mixed with 0.5 L internal size standard and 10 L deionized formamide, denatured, and separated using an ABI 310 genetic analyzer (PE Applied Biosystems). Allele calling was performed using Genotyper 2.0 software. The marker data were then automatically exported to our database (Ingres database), where they were integrated with the already existing phenotype information and prepared for linkage analysis.
Linkage analysis
Linkage analysis was performed using both model-free [nonparametric (NPL)] and model-based (parametric) methods of linkage analysis.
Two-point linkage analysis
Two-point LOD scores for the different markers studied were computed using LIPED software (23) assuming both dominant and recessive models. For each model, three levels of penetrance were tested (30%, 50%, and 80%). According to recently published guidelines (24) we used a LOD score of 1.9 or more in our whole genome screen as evidence for linkage and a LOD score above 3.3 as evidence for significant linkage. All linkage analyses were performed assuming a population prevalence of 1% for both diseases, based on the disease prevalence data in the literature (25, 26) . Based on the assumed disease prevalence of 0.01, the gene frequency was adjusted according to the model used (dominant or recessive) and the penetrance used, assuming Hardy-Weinberg equilibrium.
Multipoint linkage analysis
Multipoint LOD scores were computed by the GeneHunter program (27) using all the markers on each chromosome. Multipoint linkage analysis yields the maximum information for each individual for the area of interest. Using GeneHunter, we set the inheritance parameters identical to those that gave the maximum LOD scores (MLS) in the two-point analyses. Marker placement and distances for the multipoint analysis were obtained from the Genethon maps (21) . For the multipoint linkage analysis, we assumed a population prevalence of 1% for both diseases and adjusted the gene frequency accordingly.
NPL analysis
Our families were multiplex, with 57% unaffected individuals ( Table  1) . Under such conditions some information is lost in the NPL analysis (i.e. the haplotype information of the unaffected individuals is not used), and the resulting NPL scores are lower. However, as the mode of inheritance of the AITDs is not known, we performed NPL analysis as a check. NPL scores were computed using the GeneHunter algorithm for multipoint NPL scores. Whole chromosomes were analyzed, and the marker mapping information was obtained from the Genethon maps (21) .
Affectedness and disease models
The AITDs include GD and HT. It was not clear whether the susceptibility genes for these two disorders were unique or common to both diseases. Indeed, both disorders occur in the same family, and in our dataset 36% of the families included first degree relatives with GD and HT. Therefore, we analyzed the data using three models: 1) all AITD patients were considered as affected (loci identified using this model would confer susceptibility for both GD and HT); 2) only GD patients were considered as affected (under this model HT patients were considered as unaffected even if they had relatives with GD); and 3) only HT patients were considered as affected (under this model GD patients were considered as unaffected even if they had relatives with HT). Family members with thyroid autoantibodies alone were classified as unaffected. In addition, we tested the dataset for heterogeneity. Heterogeneity testing (␣) was also performed using GeneHunter (27) .
Power calculations
Simulation studies were performed to assess the power of our 56 families to detect linkage, and to assess the maximum attainable LOD scores for our dataset. We assumed a penetrance of 30% for our simulations based on the reported 30% concordance rate in monozygotic twins (8) . The simulation software used for the power calculations (28) generated 56 families that were homologous to the families that we included in our study. The simulations demonstrated that using a dataset of 56 families gave statistical power to reject linkage out to 10 centimorgans (cM; ϭ 0.1), at a penetrance as low as 0.3. Our families were, therefore, sufficient to reject linkage for the tested markers. Simulations also showed that we had the power to detect linkage at a penetrance of 0.3 using the 56 families. The MLSs were more than 4.0 for data generated with a marker at a recombination fraction () of 0.01 from the disease gene, and more than 2.8 for a marker at ϭ 0.05 from the disease gene. The theoretical maximum attainable LOD score in our dataset was 6.7, assuming the recessive model and ϭ 0.01. Table 1 shows the clinical characteristics of the 56 families studied. Fourteen (25%) had only GD-affected members, 22 (39%) had only HT-affected members, and 20 (36%) had both GD-and HT-affected first degree relatives. Of the 151 affected individuals, 132 (87.4%) were females, and the affected female/male (F:M) ratio (7:1) was in accordance with that reported in the literature (29) . Thirty-four percent of the clinically and biochemically unaffected family members had thyroid antibodies, similar to the incidence reported in previous studies (10, 30) . Interestingly, the F:M ratio in the thyroid antibody-positive, unaffected individuals was 1:1, i.e. much lower than the F:M ratio in the affected family members.
Results
Characteristics of the study sample
Whole genome screening for the AITD genes
For mapping the AITD genes (i.e. genes causing both GD and HT), individuals with either GD or HT were considered affected. Whole genome screening for the AITD genes revealed only one locus on chromosome 6 that showed evidence for linkage with both GD and HT (Fig. 1A) . This locus was designated AITD-1. The two-point MLS was 2.2 for marker D6S257 (80 cM) obtained for the recessive model at a penetrance of 30% and a recombination fraction of 0.01 (Fig.  1A and Table 2 ). To fine-map AITD-1 we performed a multipoint analysis using a genetic map for chromosome 6 based on the Genethon maps (http://www.genethon.fr). The order of the markers and recombination fractions of the Genethon maps were verified in our dataset. Multipoint linkage analysis localized AITD-1 to within an approximate interval of 8 cM between markers D6S1610 and D6S257. The multipoint MLS was 2.9 ( Fig. 1B and Table 2 ), which demonstrated strong evidence for linkage (24) . Further testing showed little evidence for heterogeneity in our dataset (␣ ϭ 0.92; maximum heterogeneity LOD score, 2.96). Nonparametric LOD score analysis was performed using the GeneHunter program and gave a maximum multipoint NPL score of 2.3 (P ϭ 0.0024) at the same locus. Thus, the NPL analysis supported the evidence for linkage in that region.
Whole genome screening for Graves' disease genes
For screening the unique GD genes (i.e. genes causing GD but not HT), we defined as affected only those individuals with GD. Six loci on chromosomes 1, 2, 3, 6, 9, and 13 gave LOD scores higher than 1.0 but lower than 1.5. Three loci gave two-point LOD scores of 1.9 or more, which was considered evidence for linkage (24) : D14S81 (designated GD-1) on chromosome 14 (two-point MLS, 2.1), D20S195 (designated GD-2) on chromosome 20 (MLS, 3.2), and DXS8020 (designated GD-3) on chromosome X (MLS, 1.9; Fig. 2A and Table 2 ). At two loci (GD-1 and 2) the MLS was obtained for the recessive model, at a penetrance of 30% and a recombination fraction of 0.01, and at GD-3 the MLS was obtained at a penetrance of 40% (Table 2 ). This suggested that the in -FIG. 1 . A, Whole genome analysis for loci linked with both GD and HT. The x-axis shows the relative marker positions on each chromosome, and the y-axis shows the LOD score obtained for each marker on every chromosome. Only one locus on chromosome 6 (marked by an asterisk) gave a LOD score above 2. This was designated AITD-1. Even though AITD-1 is on chromosome 6, this locus is 20 cM centromeric to the HLA region. B, Multipoint analysis for chromosome 6 . The x-axis shows the relative marker position in centimorgans, and the y-axis shows the multipoint LOD score. The maximum multipoint LOD score was 2.9 obtained between markers D6S1610 and D6S257.
heritance of the three GD susceptibility genes and that of the disease were recessive with approximately 30% penetrance. These penetrance results were compatible with twin data showing 30% concordance between identical twins (31) . Multipoint analysis confirmed these results, giving higher multipoint LOD scores at GD-1, -2, and -3; the maximum multipoint LOD scores were 2.5 for GD-1, 3.5 for GD-2, and 2.5 for GD-3 (Fig. 2, B , C, and D, and Table 2 ). The NPL scores were also supportive of linkage (1.9 for GD-1, 2.4 for GD-2 and 1.8 for GD-3; Table 2 ). The other six loci that gave positive LOD scores for GD (Ͼ1.0) proved to be false positives. They each gave negative LOD scores in the multipoint analysis that used the information from all markers on a chromosome.
Fine-mapping of GD-2
GD-2 on chromosome 20 gave the highest parametric LOD score and NPL score. We, therefore, fine-mapped GD-2 to create a framework for the identification of the susceptibility gene in this region. We analyzed 11 closely spaced markers in the region for critical recombinants in the affected family members. Using this approach, critical recombinants were found between markers D20S107 and D20S466 as the centromeric boundary of GD-2, and between D20S855 and D20S108 as the telomeric boundary of GD-2. Therefore, GD-2 was localized to a 1.0-cM interval between markers D20S107 (55 cM) and D20S108 (56 cM; Fig. 3 ). 
FIG. 2. A, Whole genome analysis for loci linked with GD only. The x-axis
shows the relative marker positions on each chromosome, and the y-axis shows the LOD score obtained for each marker on every chromosome. Three loci on chromosomes 14, 20, and X (marked by asterisks) gave LOD scores of 1.9 or more. These were designated GD-1, -2, and -3, respectively. B, Multipoint analysis for chromosome 14. The maximum LOD score was 2.5, and it was obtained between markers D14S81 and D14S1054. C, Multipoint analysis for chromosome 20. The maximum LOD score was 3.5, and it was obtained between markers D20S195 and D20S107. D, Multipoint analysis for chromosome X. The maximum LOD score was 2.5, and it was obtained between markers DXS8020 and DXS1106.
Interactions between the GD susceptibility loci
The 3 loci contributing to the susceptibility to GD may each exert their effects independently in GD or may interact to contribute synergistically to the genetic susceptibility to GD. We studied the interactions among the 3 GD loci by performing a regression analysis of the LOD scores obtained at the 3 loci for each of the families. In the regression analysis, we tested whether there were correlations between the individual family LOD scores obtained for GD-1, -2, and -3. This analysis showed a statistically significant correlation between the individual family LOD scores obtained for GD-1 and GD-2 (r ϭ 0.7; P Ͻ 0.0001) and between the individual family LOD scores obtained for GD-1 and GD-3 (r ϭ 0.5; P ϭ 0.008). However, there was no correlation between the LOD scores for GD-2 and GD-3 (r ϭ 0.1; P ϭ 0.4). This analysis suggested that in most of the families the genetic susceptibility to GD was conferred by an interaction between GD-1 and GD-2 or between GD-1 and GD-3. Additionally, when we summed the LOD scores at the 3 loci for each family, it showed that at least 1 locus was positive in 91% of the families. This may suggest that GD-1, -2, and -3 were responsible for most of the genetic susceptibility to GD in our dataset. In only a minority of the GD families (3 of 34) did 2 of the loci give negative LOD scores, and negative LOD scores for all 3 loci were not obtained for any family (Fig. 4) .
Whole genome screening for Hashimoto's disease genes
For screening the unique HT genes (i.e. genes causing HT but not GD), we defined as affected only individuals with HT. Whole genome screening for HT in all of our HT families did not show any locus giving a LOD score of 1.9 or more (Fig. 5A) . However, two loci, D12S351 on chromosome 12 and D13S173 on chromosome 13, gave LOD scores of 1.7 and 1.8, respectively (Fig. 5A and Table 2 ). On multipoint analysis D13S173 gave a maximum LOD score of 2.1, which was suggestive of linkage (24) and was designated HT-1 ( Fig. 5B and Table 2 ), whereas D12S351 gave a maximum LOD score of Ϫ0.8 with evidence of heterogeneity (heterogeneity LOD score, 2.3; ␣ ϭ 0.47; Table 2 ). To try and identify the subgroup of HT families linked to the chromosome 12 locus, we retested chromosome 12 for two subsets of our HT families based on their geographic origins. This analysis demonstrated that the locus showed strong evidence of linkage only to the European HT families, giving a maximum multipoint LOD score at D12S351 of 3.8 for the recessive model at 80% penetrance (Fig. 5C ). The North American HT families gave a negative multipoint LOD score at D12S351 using the same parameters for analysis.
Interactions between GD and HT
As only one locus (AITD-1) was found to confer susceptibility to both GD and HT, we tested whether this locus contributed equally to the development of GD and HT in all of our families. For this analysis, we divided the families into two subsets: 1) families in which all affected individuals had either GD or HT (the exclusive GD/HT families), and 2) families in which both GD and HT affected relatives were found (the mixed families). The analysis showed that the maximum LOD score obtained for the mixed families was 2.2, whereas the maximum LOD score obtained for the exclusive GD/HT families was 0.7 (Table 3) . This suggested that AITD-1 contributed mostly to the susceptibility to GD and HT in families in which both diseases coexisted. However, AITD-1 had a less important contribution, relative to GD-1, -2, and -3 . The x-axis shows the family number, and the y-axis shows the cumulative LOD score for each family. The family order on the x-axis was determined by increasing the cumulative LOD score.
the unique GD and HT loci (i.e. GD-1, -2, and -3 and HT-1), in families in which exclusively GD-or HT-affected individuals were found. A common genetic background may, therefore, exist for GD and HT, but mostly in mixed families. In GD-only or HT-only families, the genetic susceptibility was mostly conferred by genes unique to each disease.
Discussion
The mechanisms underlying the genetic predisposition to AITD are unknown. Although a hereditary component in the pathogenesis of these diseases has long been recognized, the inheritance appears to be complex, involving multiple genes with variable penetrances. Moreover, the genetic relationship between GD and HT and the familial and sporadic forms of these diseases is not known. The problem, until now, has been addressed by studying a variety of candidate genes, mainly by association studies. As it was assumed that immune dysregulation and/or thyroid antigen presentation may be involved in the generation of AITD, the candidate genes tested included genes involved in immunoregulatory pathways, and genes encoding for the major thyroid autoantigens. These have included the HLA genes (reviewed in Ref. (42, 43) , giving relative risks of 2.0 -5.0 (43) (44) (45) . Recently, Gough et al. reported evidence of association (relative risk , 2.72) between GD and the haplotype DRB1*0304-DQB1*02-DQA1*0501 using family studies (transmission disequilibrium test) (46) . The association of HT with HLA has been weaker (47) . However, our own studies (48, 49) and those of others (50) have shown no linkage between AITD and the HLA region, indicating that the HLA genes made only a small contribution to the overall genetic susceptibility to GD (51, 52) .
Outside the HLA region, only the CTLA-4 gene has been found to be associated with the AITDs, giving a relative risk of about 2.0 (40, 53, 54) . However, the association between CTLA-4 and AITD has not been consistently confirmed in all studies (55) . Recently, Pearce et al. (56) reported linkage between the CTLA-4 region and AITD. However, in view of the finding of linkage to the CTLA-4 gene region coupled with relatively weak association of this gene with AITD, it is possible that other genes in the regions are involved in the genetic susceptibility to AITD. The CTLA-4 gene region contains other nearby candidate genes for thyroid autoimmunity, including CD28, STAT-1 and -4 (signal transducer and activator of transcription), caspases 8 and 10, and cAMP response element-binding protein-1 (http://gdbwww. gdb.org/). Indeed, although we found no evidence of linkage between the CTLA-4 gene and the familial AITD, we did obtain low positive LOD scores (1.0) for CTLA-4 at higher recombination fractions, suggesting that a gene in the region (not CTLA-4) may be involved in susceptibility to AITD (52) . More studies on the CTLA-4 gene region and fine-mapping of the locus are needed to identify the susceptibility gene in this region.
As only two of the many candidate genes tested (HLA and CTLA-4) gave low relative risk associations, they could not explain the familial clustering of the AITDs. In the present study we used the whole genome screening approach to dissect the genetic susceptibility to familial GD and HT. Six loci were identified that showed evidence of linkage with AITD: AITD-1, which was linked with both GD and HT; GD-1, -2, and -3, which were linked with GD only; HT-1, which was linked with HT in all of the families; and HT-2, which showed evidence for linkage with HT in a subset of the families.
The AITDs are unique. Although their clinical manifestations are different, they share common immunopathogenetic mechanisms. Therefore, it has been proposed that they may share a common genetic susceptibility (57). Our results amplify this simple concept. We found evidence for a shared susceptibility locus (AITD-1) between GD and HT in families in which both diseases occurred. However, in the families in which only GD or HT was found, the genetic susceptibility was mostly unique to GD or HT. These results suggested that the familial forms of GD and HT may present in at least three forms according to their genetic susceptibility: 1) families in which only GD occurs, 2) families in which only HT occurs, and (3) families in which both diseases occur.
AITD-1, which is located close to the HLA region but is distinct from it, may confer susceptibility to both GD and HT. This locus is more likely to harbor a general thyroid autoimmunity gene than a disease-specific gene. Moreover, the finding of a major systemic lupus erythematosus (SLE) locus in the same location as AITD-1 may imply that a general autoimmunity gene may be located in this region. Indeed, SLE and AITD are known to be associated in the same individuals and to run together in families (58, 59) .
The results demonstrated that our HT phenotype was heterogeneous and may need to be redefined. In our study we defined all patients with hypothyroidism and positive thyroid antibodies as having HT. However, using this broad definition, only one locus (HT-1) was found to be weakly linked with familial HT (multipoint MLS, 2.1), and one locus (HT-2) showed definite evidence for heterogeneity. It is likely, therefore, that HT is a much more heterogeneous disease than GD and that our current definition of HT included several types of autoimmune thyroiditis with differing immunogenetic etiologies. It may be necessary to modify our current definitions of HT using additional criteria, such as the presence of goiter, the age of onset, ethnicity, and the levels of thyroid antibodies. This conclusion was supported by the finding of a locus on chromosome 12 (HT-2) that was strongly linked with HT only in our European families (MLS 3.8), which indicated a geographic difference or a selection bias. However, our North American families were also of European descent.
Of the three loci found to be linked exclusively with GD, GD-2 gave the highest LOD score of 3.5 and was analyzed further. By fine mapping we were able to limit the boundaries of GD-2 to a 1-cM region. This will provide a framework for the identification of GD-2. If GD-2 represented a gene involved in immune regulation it would be expected to cause susceptibility to other autoimmune diseases. Indeed, another SLE locus was recently mapped to the same region of GD-2 (60, 61). As described previously, it is well known that SLE and other autoimmune conditions are associated with AITD and sometimes present in the same families or in the same individuals. Identification of common autoimmunity genes may help explain this clustering, as seen in autoimmune polyglandular syndrome type I (62) .
Complex diseases are likely to be caused by the interaction of several genes, and their combined effects may differ in different individuals and families (6) . In type I diabetes mellitus at least 12 susceptibility loci have been identified by several groups (63) (64) (65) (66) , and in murine SLE 12 loci have been identified (67, 68) . In our dataset, three distinct loci were found to be linked with GD, and our analysis showed evidence for their interaction contributing to the overall susceptibility to GD. Although the combined effects of GD-1, -2, and -3 were not identical in the different GD families, at least one of the loci contributed to the genetic predisposition to GD in 91% of our families. A similar finding of loci interaction was recently reported in murine lupus (69) . The molecular basis for the interactions between susceptibility genes in complex diseases is unknown. In type I diabetes, where two of the genes (HLA-DR and insulin VNTR) have been identified, the molecular interaction remains unclear. Is this the cumulative effect of increased statistical risk (similar to multiple environmental factors contributing to the susceptibility to a disease)? Or, are there biological interactions between the susceptibility genes or their products to induce the susceptible phenotype? To better understand these effects we have to identify all of the genes involved and their molecular mechanisms in inducing susceptibility to autoimmune diseases.
